GLIOBLASTOMA MULTIFORME

This study tests an experimental drug called NEO100 (perillyl alcohol) in people with recurrent or worsening grade III or IV gliomas that have an IDH1 mutation. The goal is to find a safe dose and see if it helps patients live longer. Participants take the drug four times daily i…

This study tests whether giving two cancer drugs (cetuximab and bevacizumab) directly into the brain's blood vessels each month is safe and can shrink or control relapsed brain tumors in people under 22. About 20 participants with specific types of glioma will receive the treatme…

This study tests whether adding focused ultrasound (NaviFUS) to the standard drug Avastin can help people with recurrent glioblastoma, an aggressive brain cancer. About 32 adults whose tumor has returned after prior treatment will be randomly assigned to receive Avastin alone or …

This study tests a treatment for people with aggressive brain tumors (glioblastoma, anaplastic astrocytoma, or gliosarcoma) that have come back or are newly diagnosed. The treatment combines a genetically modified herpes virus (M032) that delivers an immune-boosting protein (IL-1…

This study tests a new way to deliver a standard brain cancer drug (bevacizumab) using focused ultrasound and microbubbles in 10 people whose glioblastoma has returned. The goal is to see if this combination is safe and can help control tumor growth for longer. Participants must …

This study tests whether a strict ketogenic diet (high fat, low carb) can help people with a new diagnosis of glioblastoma, an aggressive brain cancer, live longer. About 170 participants will be randomly assigned to either the keto diet or standard dietary advice, while all rece…

This study tests whether adding the drug tarlatamab to standard radiation is safe and effective for cancers that have a protein called DLL3. About 30 adults with cancers like melanoma, lung cancer, or glioblastoma will receive the combination. The goal is to find the best timing …

This study tests whether a device called TheraSphere GBM is safe for people whose glioblastoma brain tumor has come back. It delivers tiny radioactive beads directly to the tumor through blood vessels. The trial will enroll 36 adults and watch for serious side effects like brain …

This study tests whether adding an experimental pastille (APG-157) to standard bevacizumab can help people with recurrent high-grade glioma, a serious brain cancer. About 30 participants will take APG-157 daily by dissolving pastilles in their mouth, while continuing bevacizumab.…

This study tests a new drug called LMP744 in 40 adults whose glioblastoma (a type of brain cancer) has come back after standard treatment. The drug is given through a vein for 5 days each month for up to a year. The goal is to see if it can shrink tumors or slow their growth.

This early-stage trial tests whether adding the immunotherapy drug retifanlimab to standard treatments (carmustine wafers, radiation, and possibly temozolomide) is safe and helps people with newly diagnosed glioblastoma, an aggressive brain cancer. About 50 adults who have alread…

This study tests whether adding two different drug combinations after radiation can help children and young adults with high-grade gliomas (including DIPG) live longer. One group receives ribociclib plus everolimus, and another receives ribociclib plus temozolomide, based on the …

This early-stage trial tests a specially engineered virus, G207, in children and young adults (ages 3 to 21) whose cerebellar brain tumors have come back or not responded to standard treatments. The virus is injected directly into the tumor, and a single low dose of radiation is …

This early-phase study tests a new approach for people with recurrent high-grade astrocytoma, a serious brain cancer. Participants receive a virus-based gene therapy injected into the tumor cavity during surgery, followed by targeted radiation. The main goal is to find the safest…

This study tests whether adding the drug ruxolitinib to standard treatment (radiation and temozolomide) helps people with newly diagnosed glioblastoma live longer. About 190 adults will be randomly assigned to receive either the standard treatment alone or standard treatment plus…

This early-stage study tests a radioactive drug called 131I-TLX101 given alongside standard treatment for people newly diagnosed with glioblastoma, an aggressive brain cancer. The main goal is to find a safe dose and check for side effects. About 12 adults who have had surgery fo…

This study tests whether combining an immunotherapy drug (pembrolizumab) with targeted radiation before surgery is safe and can help people with recurrent glioblastoma, an aggressive brain cancer. About 10 adults whose tumor has returned after prior treatment will receive this co…

This study tests whether giving patients their own gene-modified stem cells can protect their bone marrow during high-dose chemotherapy for glioblastoma, an aggressive brain cancer. About 16 adults who recently had most of their tumor removed will receive the modified cells along…

This study tests a drug called lorlatinib in children (ages 1-21) with a newly diagnosed, aggressive brain tumor that has a specific genetic change (ALK or ROS1 fusion). The goal is to see if the drug can shrink or control the tumor and to check its safety when given alone or wit…

This early-stage study tests whether a new type of immune cell therapy (CAR T-cells) is safe for people with glioblastoma that has come back or not responded to standard treatment. The cells are given directly into the fluid around the brain. The main goal is to check for side ef…

This early-phase study tests whether combining targeted radiation with an immunotherapy drug (atezolizumab) before surgery can help control glioblastoma, a fast-growing brain cancer. Twelve newly diagnosed patients will receive two weeks of treatment, then undergo standard surger…

This study tests a new gene therapy (HSV-tk) plus valacyclovir, along with radiation and chemotherapy, in people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if this combination can help patients live longer. About 62 adults whose cancer has returne…

This study tests whether chemotherapy alone works as well as the standard combination of chemotherapy and radiation for elderly or frail patients with a type of brain cancer called glioblastoma. About 107 participants aged 65 and older with limited physical function will be rando…

This study tests a new approach for people with a recently diagnosed aggressive brain cancer called glioblastoma. A device with 9 ultrasound emitters is implanted in the skull to temporarily open the blood-brain barrier, allowing immune-boosting drugs to reach the tumor more effe…

This study tests a new method called sonobiopsy that uses ultrasound to release DNA from brain tumors into the blood, making it easier to detect without surgery. Researchers will enroll 40 adults with suspected glioblastoma to see if this approach can identify tumor mutations fro…

This study is collecting blood and urine samples from 200 adults with glioblastoma (a serious brain tumor) who are receiving radiation therapy. Researchers want to see if levels of two proteins, VEGF and MMP, can help predict whether the tumor will come back within a year. The go…

This study aims to analyze the genetic makeup of brain tumors in children, teens, and young adults (ages 1 to 39) newly diagnosed with high-grade glioma, including a type called DIPG. By identifying specific genetic changes in each tumor, researchers hope to match patients with m…

This study collects samples of glioblastoma (a type of brain tumor) and blood from 120 adults during standard surgery. Researchers will examine tissue from different parts of the same tumor to see how they differ. The goal is to learn more about the tumor's structure and behavior…

This study is testing a new combined MRI and PET scan to measure how brain tumors use energy. Researchers will compare scan results with tissue samples from 50 adults with glioblastoma who need surgery. The goal is to improve imaging, not to treat the disease directly.